Antibody responses could explain why some patients fail botulinum toxin type A (BoNT/A) treatment of hyperactive detrusor or sphincter dysfunction, according to German investigators.

 

Heinrich Schulte-Baukloh, MD, of Charité Medical School of Humboldt University in Berlin, and his colleagues studied 25 patients (mean age, 28.3 years; range, 11-75 years) who had received at least one previous detrusor and/or sphincter injection with BoNT/A. They looked at the presence of BoNT antibodies (BoNT/A-AB) and correlated this with clinical findings.

BoNT/A-AB titers were clearly positive in four patients, of whom three experienced complete therapy failure, the researchers reported in the International Journal of Urology (2008;15:405-415). In two patients, antibodies developed after just one treatment session.


Continue Reading

“In patients with clinically complete therapy failure in whom no obvious other causes can be determined (such as progressive disease in a patient with multiple sclerosis), screening for BoNT/A-AB should be carried out,” they concluded.